Cemiplimab

Evidence Level: L5

Predicted Indications: 5

Cemiplimab

Pharmacist Assessment Report

Cemiplimab: anti-PD-1 monoclonal antibody → gallbladder adenosquamous carcinoma (gallbladder adenosquamous carcinoma)

One-Sentence Summary

Cemiplimab is an anti-PD-1 antibody (immune checkpoint inhibitor) marketed in Australia as Libtayo. The TxGNN model predicts it may be effective for gallbladder adenosquamous carcinoma, but no clinical trials and no publications are currently available for this disease, so the prediction rests on the model alone.

Quick Overview

Item	Content
Original Indication	Not recorded in the local data
Predicted New Indication	gallbladder adenosquamous carcinoma
TxGNN Prediction Score	0.9999
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	1 (valid: 1)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the data compiled for this report. Pharmacology data show that cemiplimab is an antibody against human PD-1 (PDCD1) that blocks the PD-1/PD-L1 interaction (IC50 below 1 nM in an ELISA). This releases the brake on T-cell activity against tumours.

The predicted disease has a squamous component, and squamous-type cancers can express PD-1/PD-L1 pathway biology that cemiplimab targets. However, this link is speculative. Biliary tract tumours are generally poorly immunogenic, and no study of cemiplimab in gallbladder adenosquamous carcinoma was found. The high score most likely reflects the squamous histology association rather than validated biology.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 13135H	Libtayo	Solution concentrate for I.V. infusion 350 mg in 7 mL	Not recorded in the local data

Cytotoxicity

Item	Content
Cytotoxicity Classification	Immunotherapy (PD-1 checkpoint inhibitor)
Myelosuppression Risk	Low; not a conventional cytotoxic agent. Please refer to the Product Information (PI) warnings and precautions
Emetogenicity Classification	Low
Monitoring Items	Please refer to the PI; typically FBC, liver, renal and thyroid function, and monitoring for immune-related adverse events
Handling Protection	Please refer to the PI and local institutional policy

Safety Considerations

Drug Interactions: Ten interaction records were found. Nine are moderate-level interactions with systemic corticosteroids: hydrocortisone, triamcinolone, dexamethasone, betamethasone, budesonide, prednisolone, prednisone, methylprednisolone and deflazacort. The tenth is the pharmacological target record (PD-1), which is not a drug interaction.

Please refer to the TGA-approved Product Information (PI) for warnings and contraindications.

Conclusion and Next Steps

Decision: Hold

Rationale: The prediction has a very high model score (0.9999) but no supporting trials or publications for gallbladder adenosquamous carcinoma, so it stays at evidence level L5. Biliary tumours are generally poorly immunogenic, which adds caution.

To proceed, the following is needed:

Literature and trial searches specific to PD-1 blockade in biliary tract and adenosquamous carcinomas
PD-L1 expression and mutational burden data for gallbladder adenosquamous tumours
Detailed mechanism of action data
Review of the TGA Product Information for warnings and contraindications
Safety review for use in this patient population, including corticosteroid interactions
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.